Table 3

Incidence of serious infections among biologic users with PsO or PsA, overall and by drug class

All biologic classesIL-17IL-12/23TNF
Total cohort
 Number of treatment episodes11 560214828826530
 Total person-years of follow-up9264152824615275
 Incident serious infections, n (%)190 (2)32 (1)32 (1)126 (2)
 Incidence rate (95% CI), per 100 person-years2.1 (1.8 to 2.4)2.1 (1.5 to 2.9)1.3 (0.9 to 1.8)2.4 (2.0 to 2.8)
PsO
 Number of treatment episodes9691190326445144
 Total person-years of follow-up8010140623114293
 Incident serious infections, n (%)156 (2)26 (1)29 (1)101 (2)
 Incidence rate (95% CI), per 100 person-years2.0 (1.7 to 2.3)1.9 (1.2 to2.7)1.3 (0.9 to 1.8)2.4 (1.9 to 2.8)
PsA
 Number of treatment episodes55179448883685
 Total person-years of follow-up41596056472907
 Incident serious infections, n (%)105 (2)14 (1)13 (1)78 (2)
 Incidence rate (95% CI), per 100 person-years2.5 (2.1 to 3.1)2.3 (1.3 to 3.7)2.0 (1.1 to 3.3)2.7 (2.1 to 3.3)
Biologic-naïve
 Number of treatment episodes599533213444319
 Total person-years of follow-up501923712173565
 Incident serious infections, n (%)**11 (1)80 (2)
 Incidence rate (95% CI), per 100 person-years2.0 (1.6 to 2.4)3.4 (1.6 to 6.3)0.9 (0.5 to 1.6)2.2 (1.8 to 2.8)
Biologic experienced
 Number of treatment episodes5565181615382211
 Total person-years of follow-up4.246129212441710
 Incident serious infections, n (%)91 (2)24 (1)21 (1)46 (2)
 Incidence rate (95% CI), per 100 person-years2.1 (1.7 to 2.6)1.9 (1.2 to 2.7)1.7 (1.1 to 2.5)2.7 (2.0 to 3.5)
  • *Clinical description of cells with 10 or fewer observations suppressed per data license.

  • IL, interleukin; TNF, tumour necrosis factor.